MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION
The authors report the 5-year follow-up data for the SOLO1 trial. Progression-free survival (PFS) was significantly longer with olaparib compared with placebo, and durable PFS benefits were seen with 2 years of maintenance olaparib therapy in patients with BRCA-mutated, newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer with a complete or partial response after […]
